Quadrivalent Flu Shot Approved in Mainland China
The only imported quadrivalent seasonal influenza vaccine approved for use in individuals aged three years and older has been listed in 26 provinces and municipalities in China.
Clover Biopharmaceuticals, Ltd. today announced the launch of AdimFlu-S (QIS) in mainland China.
“The launch of AdimFlu-S in mainland China – our second commercialized product – strengthens Clover’s leading respiratory vaccine franchise and contributes to our financial sustainability and future growth,” said Joshua Liang, Chief Executive Officer and Executive Director of Clover, in a press release on September 12, 2023.
AdimFlu-S (QIS) is a quadrivalent split inactivated vaccine that can be used to prevent influenza. It contains hemagglutinin from four influenza virus strains (two A and two B).
This quadrivalent improves its ability to achieve high vaccine effectiveness, regardless of which influenza B strain becomes seasonally prevalent, compared to trivalent flu shot options, says the company.
AdimFlu-S gained approval from the China National Medical Products Administration in January 2022.
As of September 2023, over 100 flu shot candidates are in development globally.